Proactiveinvestors recommends
Additional Information
Market: AIM
Sector: Pharmaceuticals
EPIC: EAH
Latest Price: 224.00  (0.45% Ascending)
52-week High: 258.50
52-week Low: 186.50
Market Cap: 123.36M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Eco Animal Health Group Plc
www.ecoanimalhealthgroupplc.com

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. Our products for these growth markets promote well-being in animals. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.

Full Eco Animal Health Group Plc profile here
Pdf

ECO Animal Health forms North America distribution JV

17th Mar 2010, 7:39 am
ECO Animal Health forms North America distribution JV

ECO Animal Health Group PLC (AIM: EAH) said ECO Animal Health Ltd has formed a joint venture with Pharmgate LLC of Ramsey, New Jersey, aimed at distributing the partners’ veterinary products in the North American livestock and poultry markets.

Pharmgate is the wholly-owned US subsidiary of Jinhe Biotechnology Ltd of China.

The venture is called Pharmgate Animal Health LLC and will benefit from the manufacturing and product development experience of its owners to bring to market their ranges of extensively used medicated feed additives and new therapeutic compounds for livestock and poultry, backed by a specialist sales and technical team.

ECO Animal Health Group CEO Marc Loomes said: "This is an important step in the global commercialisation of Aivlosin, our novel antibiotic for the treatment of enteric and respiratory disease in swine and poultry. Pre-approval studies in the US market have shown similar performance of Aivlosin to that seen in markets where the product is already being successfully sold, including Europe, Central and Latin America, China, Japan, South East Asia and Africa.”

Pharmgate general manager Colin Gray commented: “Our FDA-approved (Food and Drug Administration) manufacturing facilities in China meet the highest international quality, safety and environmental standards and are well-known to the industry. We look forward to satisfying our customers' requirements for a streamlined, no-nonsense source of key animal health products.”

ECO Animal Health Group develops, registers and markets pharmaceutical products for global animal health markets. Its products for these growth markets promote well-being in animals and include the novel macrolide antibiotic, Aivlosin, as well as a range of generic therapeutic products.

Jinhe Biotechnology Co produces chlortetracycline feed grade, chlortetracycline hydrochloride, salinomycin and other animal health compounds. The company has marketing or supply approvals for these products in most major markets throughout the world.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.